Risk of Hepatocellular Carcinoma in Patient With Liver Cirrhosis
Study of Hepatocellular Carcinoma Risk in Patient With Liver Cirrhosis
調査の概要
状態
条件
詳細な説明
Patients will be enrolled after hepatic ultrasonography control and they will be submitted to hepatic vein pressure gradient and liver biopsy.
The study have four research lines:
Task # 1: transcriptomic characterization of liver tissue. During hepatic vein pressure gradient , liver tissue will be extracted with transjugular catheter equipped with a biopsy device. Tissue will be used to extract microRNA to define molecular signature.
Task # 2: Proteomic characterization of liver tissue. Protein expression changes will be analyze with MALDI-TOF
Task # 3: Metabolomic features on serum of patient with cirrhosis. Metabolomics is defined as the quantitative measurement of the dynamic multiparametric response of living systems to pathophysiological stimulus or genetic modification. Principal objective of this activity will be identify metabolites deregulated with metabolomic approach and clarify any new pathways involved in the evolution of cirrhosis to hepatocellular carcinoma.
The metabolomic analysis will be performed on sera collected in patients with cirrhosis at baseline.
Task # 4: Transcriptomic characteristics of newly diagnosed HCC. New diagnosis of hepatocellular carcinoma will undergo an eco-assisted liver biopsy. A tissue sample will be dedicated to the extraction of 'RNA. Patients will then undergo elective treatment according to international guidelines. The course of the disease and the results of therapeutic interventions will be recorded and correlated with the molecular data. Molecular signature will be obtain.
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
MO
-
Modena、MO、イタリア、41124
- 募集
- Azienda Ospedaliera Universitaria Policlinico Di Modena
-
コンタクト：
- ERICA VILLA, MD
- 電話番号：0594225308
- メール：erica.villa@unimore.it
-
コンタクト：
-
主任研究者：
- ERICA VILLA, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients with liver cirrhosis will be selected. After obtaining informed consent they will be submitted to hepatic biopsy,blood sample, HVPG with combined right heart catheterization and every 6 months to ultrasound.
Patients will be followed for 24 months thereafter or until the diagnosis of HCC, whichever comes first. In case of onset of HCC, will be performed a eco-guided biopsy.
説明
Inclusion Criteria:
- Obtaining written informed consent
- Liver cirrhosis
- Aged between 18 and 75 years
- Absence of exclusion criteria
Exclusion Criteria:
- HCC
- HIV
- Pregnancy
- Portal vein thrombosis
- Liver Transplant
- Patients' refusal to participate in clinical research
研究計画
研究はどのように設計されていますか？
デザインの詳細
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Transcriptomics characterization of liver tissue: the purpose is molecular evaluation of possible predisposing factors to development of hepatocellular carcinoma in patients with cirrhosis.
時間枠：December 2017
|
RNA sample will be collected from patients and used to obtained transcriptomic profile through microarray and microRNA. Patients will be submitted to hepatic vein pressure gradient and combined right heart catheterization. During this standard procedure liver tissue will be taken and treated for extraction of RNA. In order to obtain microarray RNA extracted will be analyzed with single color hybridization of human RNA on Agilent Whole Human Genome Oligo whereas, the extraction of microRNA will be made starting from RNA extracted with mirVana miRNA Isolation kit. |
December 2017
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proteomic characterization of liver tissue: the objective is to understand if there is a relationship between emergence of HCC and alterations of protein expression in cirrhotic liver.
時間枠：DECEMBER 2017
|
Modifications of protein expression will be examined by two-dimensional electrophoresis and MALDI-TOF.
|
DECEMBER 2017
|
|
Metabolomic features of patient with cirrhosis: principal aim of this task is to identify particular metabolites and potential new pathway involved in the evolution of cirrhosis to hepatocellular carcinoma
時間枠：DECEMBER 2017
|
Analysis will be conducted on sera collected during the screening.
These samples will be examined using liquid chromatography and mass spectrometry in order to obtain the identification of main components and their mass than, the informations will be analyzed by MarkerLynxTM software
|
DECEMBER 2017
|
|
Transcriptomics characteristics of newly diagnosed hepatocellular carcinoma: the purpose is to verify if we can predict the survival of patients considering the molecular features of HCC at first diagnosis.
時間枠：DECEMBER 2017
|
Patients with new diagnosis of hepatocellular carcinoma will be subjected to liver biopsy.
A part of biopsy will be used to extract RNA and we will try to identify molecular signature through qRT / PCR (polymerase chain reaction) and using a set of 12 up- regulated and 10 down - regulated genes previously identified.
|
DECEMBER 2017
|
協力者と研究者
捜査官
- 主任研究者：ERICA VILLA、Università di Modena e Reggio Emilia
研究記録日
主要日程の研究
研究開始
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。